January - March 2011

March 31, 2011		Takeda Appoints New Leadership for its European Pharmaceutical Development Organization
March 31, 2011		Takeda Appoints New CEO for European Commercial Business
March 30, 2011		TOP-LINE RESULTS ANNOUNCED OF PIVOTAL PHASE 3 MOTESANIB TRIAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
March 30, 2011		Takeda and DSP Sign Development, Manufacturing and Commercialization Agreement for a Cephem Antibiotic Ceftaroline in Japan
March 30, 2011		DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent Lurasidone in Europe
March 25, 2011		Takeda Plans to Expand the Sales Force and to Enhance the business infrastructure in China
March 22, 2011		Launch of Reminyl® for the treatment of Japanese patients with Alzheimer-type dementia
March 22, 2011		Takeda Submits a New Drug Application for TAK-536 in Japan, an Investigational Compound for Treatment of Hypertension
March 17, 2011		Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
March 14, 2011		Takeda’s Donation to Aid Earthquake Relief Efforts in Earthquake in Japan
March 3, 2011		Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
February 26, 2011		FDA Approves EDARBI (azilsartan medoxomil) for theTreatment of Hypertension
February 24, 2011		Takeda Establishes Endowment Course at Waseda University~Case Study Business Program to Focus on Takeda's global business~
February 24, 2011		Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
February 23, 2011		Approval of Additional Indications of "NESINA®": Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide for Type 2 Diabetes in Japan
February 21, 2011		Takeda Voluntarily Recalls its Anti-inflammatory Enzyme Preparation, Dasen® in Japan
February 19, 2011		Inauguration of Shonan Research Center
February 9, 2011		Takeda Enrolls Clinical Trial Subject in Phase 3 Study of Alogliptin in China
February 4, 2011		New Co-Promotion Agreements for Rheumatoid Arthritis Products in Japan
February 1, 2011		FDA Issues Complete Response to New Drug Application for Contrave® for the Management of Obesity
January 31, 2011		Takeda's Annual Report 2010 and CSR Data Book 2010 receive first prize in Sustainability Reporting Award
January 27, 2011		Completion of the API Manufacturing Facility for Investigational Antibody
January 24, 2011		Anti-Cancer Agent AMG 386 Enters into Phase III Clinical Trials in Japan
January 21, 2011		New Drug Application Approval for SONIAS® HD and SONIAS LD in Japan - Fixed dose combination tablet of ACTOS® and sulfonylurea for treatment of type 2 diabetes -
January 21, 2011		Takeda’s Settlement of a Lawsuit against Taiyo Pharmaceutical Industry Co., LTD. for Recall of Pansoporin® and Other Products of Takeda
January 18, 2011		Open innovation laboratory for drug discovery and development by Takeda and Kyoto University - Basic and clinical research project for CNS drugs - (TK Project)
January 11, 2011		Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone